{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:57:18Z","timestamp":1791093438150,"version":"4.1.0"},"reference-count":33,"publisher":"Japanese Pharmacological Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1254\/jphs.13r02cp","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T19:06:10Z","timestamp":1375124770000},"page":"251-256","source":"Crossref","is-referenced-by-count":30,"title":["Mithramycin, an Agent for Developing New Therapeutic Drugs for Neurodegenerative Diseases"],"prefix":"10.1254","volume":"122","author":[{"given":"Nobuhiro","family":"Osada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kosuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","unstructured":"1 Kennedy BJ, Yarbro JW, Kickertz V, Sandberg-Wollheim M. Effect of mithramycin on a mouse glioma. Cancer Res. 1968;28:91\u201397."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Ream NW, Perlia CP, Wolter J, Taylor SG 3rd. Mithramycin therapy in disseminated germinal testicular cancer. JAMA. 1968;204:1030\u20131036.","DOI":"10.1001\/jama.1968.03140250010003"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1021\/bi00231a027"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, et al. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 2006;11:2737\u20132746.","DOI":"10.1158\/1535-7163.MCT-06-0426"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Taylor DJ, Parsons CE, Han H, Jayaraman A, Rege K. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer. 2011;11:470.","DOI":"10.1186\/1471-2407-11-470"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103:962\u2013978.","DOI":"10.1093\/jnci\/djr156"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 2001;49:345\u2013354.","DOI":"10.1002\/ana.71"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Vidal R, Caballero B, Couve A, Hetz C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington\u2019s disease. Curr Mol Med. 2011;11:1\u201312.","DOI":"10.2174\/156652411794474419"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2008.12.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ferrante RJ, Ryu H, Kubilus JK, D\u2019Mello S, Sugars KL, Lee J, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease. J Neurosci. 2004;24:10335\u201310342.","DOI":"10.1523\/JNEUROSCI.2599-04.2004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Coles R, Caswell R, Rubinsztein DC. Functional analysis of the Huntington\u2019s disease (HD) gene promoter. Hum Mol Genet. 1998;7:791\u2013800.","DOI":"10.1093\/hmg\/7.5.791"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 1996;2:699\u2013703.","DOI":"10.1038\/nm0696-699"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.11207SC"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, et al. Epigenetics in the nervous system. J Neurosci. 2008;28:11753\u201311759.","DOI":"10.1523\/JNEUROSCI.3797-08.2008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Akbarian S, Huang HS. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry. 2009;65:198\u2013203.","DOI":"10.1016\/j.biopsych.2008.08.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hagiwara H, Iyo M, Hashimoto K. Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res. 2009;1301:189\u2013196.","DOI":"10.1016\/j.brainres.2009.09.010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J. 2004;18:238\u2013251.","DOI":"10.1096\/fj.03-0295com"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.008"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.02.003"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.04.009"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.05187.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31:347\u2013354.","DOI":"10.1161\/01.STR.31.2.347"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.12.007"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2010.03.017"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2011.11.001"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ting J, Lee AS. Human gene encoding the 78,000-dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation. DNA. 1988;7:275\u2013286.","DOI":"10.1089\/dna.1988.7.275"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(92)90523-R"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.11013FP"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Volpe BT, Petito CK. Dementia with bilateral medial temporal lobe ischemia. Neurology. 1985;35:1793\u20131797.","DOI":"10.1212\/WNL.35.12.1793"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl063"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.03.020"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0710-11.2011"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.087510"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/122\/4\/122_13R02CP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T11:11:12Z","timestamp":1621422672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/122\/4\/122_13R02CP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.13r02cp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}